PB2062: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF REFRACTORY HODGKIN’S LYMPHOMA.

Approximately 10 to 15 percent of patients have refractory Hodgkin's lymphoma (HL) that either does not respond to initial therapy or progresses after an initial partial response. Refractory HL poses a major problem of care, especially since there is currently no consensus regarding second or third line chemotherapy. The objective of our study is to report the epidemiological, clinical and therapeutic features of patients with refractory HL to first-line chemotherapy. This is a retrospective study including 32 patients with refractory HL treated during the period from 2015 to 2020. The patients received the first line chemotherapy according to the national MDH 2015 protocol.